Safety and Efficacy Study of a New Device for Tattoo Removal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A new mechanical device is evaluated for tattoo removal, comparing two types of needle washing fluids. 30 healthy subjects with tattoos will be treated. The study hypothesis is that the device can be used to achieve satisfactory tattoo removal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The new device (Eraser TM) uses multiple needles action with a washing fluid to remove tattoos. Healthy patients who wish to remove a tattoo will be enrolled. The study will test the removal of a small part of the tattoo (5cm2 area). Treatment lasts about 20 minutes (with local analgesia if needed), after which an absorptive bandage is put over the treated area for an hour and removed. Treatment may be performed using one of two washing fluids. For one of them, blood samples for material blood level will be taken before and several times after treatment. Pictures of the tattooed area being removed will be taken before and after treatment, and at each follow-up evaluation.

Follow up evaluations will be performed at 1 week, two weeks, one month and two months post treatment. Overall health and skin condition will be evaluated, and the tattoo area will be pictured. Efficacy of tattoo removal will be evaluated after two months, by visual estimation of the percent area that reacted to treatment, and the change in brightness (both evaluated on a 1-5 analog scale). Depending on the result of tattoo removal, and on skin condition, the study treatment will be stopped (if treatment is successful), or may be repeated (up to a limit of two additional times) if the tattoo was not completely removed.

The results of tattoo removal using both washing fluids will be analyzed and compared. A result of 3 or more on the brightness change scale will be considered as a successful treatment.

Pharmacokinetic data for washing fluid no. 2 will be collected and analyzed, to provide Cmax and AUC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tattoo Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Tattoo removal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eraser TM device, with washing fluid

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects 18 years or older, of any race
* Subject has a tattoo for removal on the back, shoulders or abdomen (areas that can usually be hidden)
* Subjects willing to participate as evidenced by signing the written informed consent

Exclusion Criteria

* Subject has a dermatological disease, active or latent (e.g. psoriasis)
* Subject has a known tendency for Keloid formation.
* Subject has a known tendency for skin hyperpigmentation.
* Subject is susceptible to Koebner reaction.
* Subject has blood transmittable diseases (HIV, HBV, HCV, etc.)
* Subject has known allergy to device components/ treatment fluids
* Subject has medical conditions that may be worsened by concomitant use of washing fluid, or worsened by local anesthesia materials.
* Subject is taking certain medications or topical preparations.
* Female subject who is pregnant or lactating.
* Subject participating in any other clinical study at the same time

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shay Efrati, MD

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research & Development Unit, Assaf-Harofeh Medical Center,

Ẕerifin, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ori Nesher

Role: CONTACT

Phone: 00-1-972-54-6511141

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HM-AHR-1 Rev. 02

Identifier Type: -

Identifier Source: secondary_id

HTA 3722; 91/06